ReviewBMC medicine2023
Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions.
Review in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- Effects of Dapagliflozin Combined with Sacubitril/Valsartan on Cardiac Electrophysiology and Quantitative Myocardial Motion Parameters in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction.Cardiovascular drugs and therapy · 2026Article
- Atrial fibrillation and atrial flutter in China: trends and projections to 2050 from GBD 2023.Internal and emergency medicine · 2026Article
- Mitochondrial dysfunction drives ZBP1-mediated PANoptosis to increase the susceptibility of heart failure with preserved ejection fraction-associated atrial fibrillation.Journal of advanced research · 2026Article
- Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF).bioRxiv : the preprint server for biology · 2026Article
- Effect of SGLT2 Inhibitors on the Efficacy of First-Time Pulmonary Vein Isolation and Clinical Course of Patients with Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation.Journal of cardiovascular development and disease · 2026Article
- Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets.Current heart failure reports · 2026Review
- Development and validation of a nomogram model based on inflammatory markers and cardiac parameters: predicting the risk of recurrence in patients with atrial fibrillation after radiofrequency catheter ablation.BMC cardiovascular disorders · 2026Article
- Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation.Journal of clinical medicine · 2026Review
- Insulin resistance as a predictor of long-term adverse cardiovascular event risk in patients with atrial fibrillation following radiofrequency catheter ablation.Frontiers in endocrinology · 2026Observational
- Long-term SGLT2 inhibitor therapy improves myocardial strain and diastolic function in HFpEF: a retrospective study linking functional recovery to reduced myocardial fibrosis.Frontiers in cardiovascular medicine · 2026Article
- Association between prognostic nutritional index and major adverse cardiovascular events in patients with atrial fibrillation combined with heart failure with preserved ejection fraction.Frontiers in nutrition · 2026Article
- Correlation of Controlling Nutritional Status Score and Systemic Immune-Inflammation Index With Frailty and Prognosis in Chronic Heart Failure Patients With Atrial Fibrillation.Cardiology research and practice · 2026Article
- Who Benefits Most? Patient Selection for Atrial Fibrillation Catheter Ablation in Heart Failure.Arrhythmia & electrophysiology review · 2026Review
- Which Patient Benefits from Guideline-directed Medical Therapy for Heart Failure and Rate Control versus Rhythm Control in Patients with Congestive Heart Failure and Atrial Fibrillation and What are Those Therapies?Arrhythmia & electrophysiology review · 2026Review
- Strengths and limitations of HFpEF probability scores in the era of precision medicine.Frontiers in medicine · 2026Review
- Machine learning to identify heart failure with preserved ejection fraction in type 2 diabetes mellitus patients.Frontiers in cardiovascular medicine · 2026Article
- Evaluating Incident Atrial Fibrillation and Incident Heart Failure as Time-varying Covariates for Time-to-Event Analysis Among Adults 55 Years and Older in the Multi-Ethnic Study of Atherosclerosis (MESA).Journal of cardiac failure · 2025Observational
- SGLT2 inhibitors and left atrial function in heart failure with reduced or mildly reduced ejection fraction.BMC cardiovascular disorders · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) and heart failure (HF) are frequently associated and can be caused or exacerbated by each other through different mechanisms. AF is particularly common in patients with heart failure with preserved ejection fraction (HFpEF) defined as left ventricular ejection fraction (LVEF) ≥ 50%, with a prevalence ranging around 40-60%.In two recent trials, treatment with SGLT2 inhibitors resulted in a lower risk of worsening heart failure or cardiovascular death than placebo in patients with HFpEF, and SGLT2 inhibitors similarly improved prognosis whether patients had AF or not at enrolment. Analyses for subgroups of interest of patients with HFpEF likely to be at higher risk of AF (particularly those with older age or obesity) similarly indicated a consistent benefit with SGLT2 inhibitors. That subgroup in patients with HFpEF is those with a history of previous HF with LVEF ≤ 40%. The EAST-AFNET 4 trial indicated that early rhythm-control therapy was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients with recent AF and cardiovascular conditions, including those with HF. In patients with AF and HF included in the CABANA trial, catheter ablation produced marked improvements in survival, freedom from AF recurrence, and quality of life compared to drug therapy. When strategies aiming at rhythm control eventually fail in patients with AF and HFpEF, a strategy of rate control with atrioventricular junction ablation and cardiac resynchronisation should be discussed since it may also reduce all-cause mortality.Finally, and in conclusion, considering that patients with AF and HFpEF may have a variety of cardiovascular and non-cardiovascular additional comorbidities, they are among those likely to have the highest clinical benefit being adherent to a holistic and integrated care management of AF following the ABC (Atrial Fibrillation Better Care) pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.